Published in Int J Cancer on February 15, 2008
Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell (2009) 5.81
Tumour heterogeneity and cancer cell plasticity. Nature (2013) 5.47
Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell (2012) 5.44
Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci U S A (2009) 4.19
Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nat Rev Cancer (2010) 4.10
Integrin alpha 6 regulates glioblastoma stem cells. Cell Stem Cell (2010) 3.82
Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell (2010) 3.70
The therapeutic promise of the cancer stem cell concept. J Clin Invest (2010) 3.26
Heterogeneity maintenance in glioblastoma: a social network. Cancer Res (2011) 2.66
Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling. Cancer Res (2010) 2.54
Autocrine VEGF-VEGFR2-Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth. J Exp Med (2012) 2.21
Brain cancer stem cells display preferential sensitivity to Akt inhibition. Stem Cells (2008) 2.12
The telomerase antagonist, imetelstat, efficiently targets glioblastoma tumor-initiating cells leading to decreased proliferation and tumor growth. Clin Cancer Res (2010) 1.96
Hypoxia increases the expression of stem-cell markers and promotes clonogenicity in glioblastoma neurospheres. Am J Pathol (2010) 1.86
Retracted Marker-independent identification of glioma-initiating cells. Nat Methods (2010) 1.84
Expression of the "stem cell marker" CD133 in pancreas and pancreatic ductal adenocarcinomas. BMC Cancer (2008) 1.82
Radiation resistance of cancer stem cells: the 4 R's of radiobiology revisited. Stem Cells (2010) 1.78
Cancer stem cells are enriched in the side population cells in a mouse model of glioma. Cancer Res (2008) 1.75
Phenotypic heterogeneity and instability of human ovarian tumor-initiating cells. Proc Natl Acad Sci U S A (2011) 1.68
Chemoresistance of glioblastoma cancer stem cells--much more complex than expected. Mol Cancer (2011) 1.64
Cancer stem cells in gliomas: identifying and understanding the apex cell in cancer's hierarchy. Glia (2011) 1.63
Potential therapeutic implications of cancer stem cells in glioblastoma. Biochem Pharmacol (2010) 1.60
Hyaluronan: a constitutive regulator of chemoresistance and malignancy in cancer cells. Semin Cancer Biol (2008) 1.52
Hyaluronan, CD44 and Emmprin: partners in cancer cell chemoresistance. Drug Resist Updat (2008) 1.49
Evidence for label-retaining tumour-initiating cells in human glioblastoma. Brain (2011) 1.48
Evidence for self-renewing lung cancer stem cells and their implications in tumor initiation, progression, and targeted therapy. Cancer Metastasis Rev (2010) 1.46
Telomeres and telomerase in normal and cancer stem cells. FEBS Lett (2010) 1.46
Current strategies for identification of glioma stem cells: adequate or unsatisfactory? J Oncol (2012) 1.40
Identification of diverse astrocyte populations and their malignant analogs. Nat Neurosci (2017) 1.39
A reproducible brain tumour model established from human glioblastoma biopsies. BMC Cancer (2009) 1.35
Activation of PI3K/Akt pathway by CD133-p85 interaction promotes tumorigenic capacity of glioma stem cells. Proc Natl Acad Sci U S A (2013) 1.32
Molecular properties of CD133+ glioblastoma stem cells derived from treatment-refractory recurrent brain tumors. J Neurooncol (2009) 1.32
Gliosarcoma stem cells undergo glial and mesenchymal differentiation in vivo. Stem Cells (2010) 1.29
Targeting A20 decreases glioma stem cell survival and tumor growth. PLoS Biol (2010) 1.27
CD133 antigen expression in ovarian cancer. BMC Cancer (2009) 1.23
CD90 is identified as a candidate marker for cancer stem cells in primary high-grade gliomas using tissue microarrays. Mol Cell Proteomics (2011) 1.16
Inconsistent immunohistochemical expression patterns of four different CD133 antibody clones in glioblastoma. J Histochem Cytochem (2011) 1.14
CD133+ melanoma subpopulations contribute to perivascular niche morphogenesis and tumorigenicity through vasculogenic mimicry. Cancer Res (2012) 1.13
A molecular screening approach to identify and characterize inhibitors of glioblastoma stem cells. Mol Cancer Ther (2011) 1.13
Side population in human glioblastoma is non-tumorigenic and characterizes brain endothelial cells. Brain (2013) 1.12
CD133: to be or not to be, is this the real question? Am J Transl Res (2013) 1.12
Oncolytic viral therapy: targeting cancer stem cells. Oncolytic Virother (2014) 1.11
Tumor-initiating and -propagating cells: cells that we would like to identify and control. Neoplasia (2010) 1.11
Allergy and inflammatory transcriptome is predominantly negatively correlated with CD133 expression in glioblastoma. Neuro Oncol (2009) 1.10
Cancer stem cells, cancer cell plasticity and radiation therapy. Semin Cancer Biol (2014) 1.08
Brain Tumor Stem-Like Cells Identified by Neural Stem Cell Marker CD15. Transl Oncol (2009) 1.06
Cancer stem cells in solid tumors: elusive or illusive? Cell Commun Signal (2010) 1.05
Targeting glioma stem cells: a novel framework for brain tumors. Cancer Sci (2011) 1.03
Glioblastomas are composed of genetically divergent clones with distinct tumourigenic potential and variable stem cell-associated phenotypes. Acta Neuropathol (2013) 1.03
What is the clinical value of cancer stem cell markers in gliomas? Int J Clin Exp Pathol (2013) 1.02
Clinical relevance of tumor cells with stem-like properties in pediatric brain tumors. PLoS One (2011) 1.02
Radioresistance of glioma stem cells: intrinsic characteristic or property of the 'microenvironment-stem cell unit'? Mol Oncol (2011) 1.01
Tumor initiating cells in malignant gliomas: biology and implications for therapy. J Mol Med (Berl) (2009) 1.01
Investigating the link between molecular subtypes of glioblastoma, epithelial-mesenchymal transition, and CD133 cell surface protein. PLoS One (2013) 1.01
A single intravenous injection of oncolytic picornavirus SVV-001 eliminates medulloblastomas in primary tumor-based orthotopic xenograft mouse models. Neuro Oncol (2010) 1.00
Targeting miR-381-NEFL axis sensitizes glioblastoma cells to temozolomide by regulating stemness factors and multidrug resistance factors. Oncotarget (2015) 1.00
Clinically relevant doses of chemotherapy agents reversibly block formation of glioblastoma neurospheres. Cancer Lett (2010) 0.98
Cancer stem cell markers in head and neck squamous cell carcinoma. Stem Cells Int (2013) 0.97
CD133/prominin1 is prognostic for GBM patient's survival, but inversely correlated with cysteine cathepsins' expression in glioblastoma derived spheroids. Radiol Oncol (2011) 0.97
Remission of invasive, cancer stem-like glioblastoma xenografts using lentiviral vector-mediated suicide gene therapy. PLoS One (2009) 0.96
The role of glioma stem cells in chemotherapy resistance and glioblastoma multiforme recurrence. Expert Rev Neurother (2015) 0.96
Therapy targets in glioblastoma and cancer stem cells: lessons from haematopoietic neoplasms. J Cell Mol Med (2013) 0.95
Cancer stem cells, epithelial-mesenchymal transition, and drug resistance in high-grade ovarian serous carcinoma. Hum Pathol (2013) 0.95
Cancer stem cells in pediatric sarcomas. Front Oncol (2013) 0.94
Glioblastoma cancer stem-like cells: implications for pathogenesis and treatment. Cancer J (2012) 0.94
CD166/activated leukocyte cell adhesion molecule is expressed on glioblastoma progenitor cells and involved in the regulation of tumor cell invasion. Neuro Oncol (2011) 0.94
Isolation of glioma cancer stem cells in relation to histological grades in glioma specimens. Childs Nerv Syst (2012) 0.94
Glioma stem cell maintenance: the role of the microenvironment. Curr Pharm Des (2011) 0.93
Primary brain tumors, neural stem cell, and brain tumor cancer cells: where is the link? Neuropharmacology (2010) 0.93
Clinical value of CD133 and nestin in patients with glioma: a population-based study. Int J Clin Exp Pathol (2014) 0.92
Intra-operatively obtained human tissue: protocols and techniques for the study of neural stem cells. J Neurosci Methods (2009) 0.92
Autocrine endothelin-3/endothelin receptor B signaling maintains cellular and molecular properties of glioblastoma stem cells. Mol Cancer Res (2011) 0.92
Origins and clinical implications of the brain tumor stem cell hypothesis. J Neurooncol (2009) 0.92
The three-layer concentric model of glioblastoma: cancer stem cells, microenvironmental regulation, and therapeutic implications. ScientificWorldJournal (2011) 0.91
A radial glia gene marker, fatty acid binding protein 7 (FABP7), is involved in proliferation and invasion of glioblastoma cells. PLoS One (2012) 0.91
Stem cell characteristics in glioblastoma are maintained by the ecto-nucleotidase E-NPP1. Cell Death Differ (2014) 0.90
Brain cancer stem cells: current status on glioblastoma multiforme. Cancers (Basel) (2011) 0.90
Integrin α3 is overexpressed in glioma stem-like cells and promotes invasion. Br J Cancer (2013) 0.89
Isolation and propagation of a human CD133(-) colon tumor-derived cell line with tumorigenic and angiogenic properties. Cell Transplant (2010) 0.89
Deconstruction of medulloblastoma cellular heterogeneity reveals differences between the most highly invasive and self-renewing phenotypes. Neoplasia (2013) 0.89
Glioblastoma: molecular pathways, stem cells and therapeutic targets. Cancers (Basel) (2015) 0.89
Overexpression of CD133 promotes drug resistance in C6 glioma cells. Mol Cancer Res (2010) 0.88
Association of stem cell marker CD133 expression with dissemination of glioblastomas. Neurosurg Rev (2010) 0.88
Cornering metastases: therapeutic targeting of circulating tumor cells and stem cells. Front Oncol (2012) 0.88
Delayed cell death associated with mitotic catastrophe in γ-irradiated stem-like glioma cells. Radiat Oncol (2011) 0.87
Cancer Stem Cell Hierarchy in Glioblastoma Multiforme. Front Surg (2016) 0.87
Glioblastoma stem cells: Molecular characteristics and therapeutic implications. World J Stem Cells (2014) 0.86
Targeted therapy of glioblastoma stem-like cells and tumor non-stem cells using cetuximab-conjugated iron-oxide nanoparticles. Oncotarget (2015) 0.86
CD133 Expression Is Not Synonymous to Immunoreactivity for AC133 and Fluctuates throughout the Cell Cycle in Glioma Stem-Like Cells. PLoS One (2015) 0.86
Human non-small cell lung cancer expresses putative cancer stem cell markers and exhibits the transcriptomic profile of multipotent cells. BMC Cancer (2015) 0.86
Brain mesenchymal stem cells: The other stem cells of the brain? World J Stem Cells (2014) 0.85
CFC1 is a cancer stemness-regulating factor in neuroblastoma. Oncotarget (2017) 0.84
Tenascin-C: a novel candidate marker for cancer stem cells in glioblastoma identified by tissue microarrays. J Proteome Res (2014) 0.84
In silico experimentation of glioma microenvironment development and anti-tumor therapy. PLoS Comput Biol (2012) 0.84
Partial biological characterization of cancer stem-like cell line (WJ(2)) of human glioblastoma multiforme. Cell Mol Neurobiol (2008) 0.83
A simplified and modified procedure to culture brain glioma stem cells from clinical specimens. Oncol Lett (2011) 0.83
In vitro Analysis of Neurospheres Derived from Glioblastoma Primary Culture: A Novel Methodology Paradigm. Front Neurol (2014) 0.83
Akt and c-Myc induce stem-cell markers in mature primary p53⁻/⁻ astrocytes and render these cells gliomagenic in the brain of immunocompetent mice. PLoS One (2013) 0.83
Complex oncogenic signaling networks regulate brain tumor-initiating cells and their progenies: pivotal roles of wild-type EGFR, EGFRvIII mutant and hedgehog cascades and novel multitargeted therapies. Brain Pathol (2011) 0.82
A proposed quantitative index for assessing the potential contribution of reprogramming to cancer stem cell kinetics. Stem Cells Int (2014) 0.82
Long-term cultures of bone marrow-derived human mesenchymal stem cells frequently undergo spontaneous malignant transformation. Cancer Res (2009) 4.58
Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci U S A (2011) 3.48
Genome-wide association study identifies three new melanoma susceptibility loci. Nat Genet (2011) 2.29
γ knife surgery versus reoperation for recurrent glioblastoma multiforme. World Neurosurg (2012) 2.28
Mutations in the CEL VNTR cause a syndrome of diabetes and pancreatic exocrine dysfunction. Nat Genet (2005) 2.22
Autophagy contributes to therapy-induced degradation of the PML/RARA oncoprotein. Blood (2010) 2.15
Critical appraisal of the side population assay in stem cell and cancer stem cell research. Cell Stem Cell (2011) 2.13
Permanent neonatal diabetes due to mutations in KCNJ11 encoding Kir6.2: patient characteristics and initial response to sulfonylurea therapy. Diabetes (2004) 2.10
Spontaneous malignant transformation of human mesenchymal stem cells reflects cross-contamination: putting the research field on track - letter. Cancer Res (2010) 2.09
Angiogenesis-independent tumor growth mediated by stem-like cancer cells. Proc Natl Acad Sci U S A (2006) 1.96
Long-range gene regulation links genomic type 2 diabetes and obesity risk regions to HHEX, SOX4, and IRX3. Proc Natl Acad Sci U S A (2009) 1.93
Assessing the phenotypic effects in the general population of rare variants in genes for a dominant Mendelian form of diabetes. Nat Genet (2013) 1.91
Expression of the "stem cell marker" CD133 in pancreas and pancreatic ductal adenocarcinomas. BMC Cancer (2008) 1.82
FTO, type 2 diabetes, and weight gain throughout adult life: a meta-analysis of 41,504 subjects from the Scandinavian HUNT, MDC, and MPP studies. Diabetes (2011) 1.75
Protein disulfide isomerase expression is related to the invasive properties of malignant glioma. Cancer Res (2006) 1.75
BRAF and NRAS mutations are frequent in nodular melanoma but are not associated with tumor cell proliferation or patient survival. J Invest Dermatol (2005) 1.66
Cancer stem cells as mediators of treatment resistance in brain tumors: status and controversies. Neoplasia (2007) 1.62
In vivo animal models for studying brain metastasis: value and limitations. Clin Exp Metastasis (2013) 1.52
Distal phalangeal creases--a distinctive dysmorphic feature in disorders of the RAS signalling pathway? Eur J Med Genet (2007) 1.45
Biochemical and functional characterization of germ line KRAS mutations. Mol Cell Biol (2007) 1.41
Expression of extracellular matrix components in a highly infiltrative in vivo glioma model. Acta Neuropathol (2002) 1.35
A reproducible brain tumour model established from human glioblastoma biopsies. BMC Cancer (2009) 1.35
Disruption of a long distance regulatory region upstream of SOX9 in isolated disorders of sex development. J Med Genet (2011) 1.34
Molecular analysis of the PI3K-AKT pathway in uterine cervical neoplasia: frequent PIK3CA amplification and AKT phosphorylation. Int J Cancer (2006) 1.32
DNA repair and cancer stem-like cells--potential partners in glioma drug resistance? Cancer Treat Rev (2008) 1.30
Biomarker profiles in serum and saliva of experimental Sjögren's syndrome: associations with specific autoimmune manifestations. Arthritis Res Ther (2008) 1.29
A novel eGFP-expressing immunodeficient mouse model to study tumor-host interactions. FASEB J (2008) 1.29
Glioma cell populations grouped by different cell type markers drive brain tumor growth. Cancer Res (2010) 1.24
In vivo models of primary brain tumors: pitfalls and perspectives. Neuro Oncol (2012) 1.21
Collagen-binding proteoglycan fibromodulin can determine stroma matrix structure and fluid balance in experimental carcinoma. Proc Natl Acad Sci U S A (2007) 1.20
From clinicogenetic studies of maturity-onset diabetes of the young to unraveling complex mechanisms of glucokinase regulation. Diabetes (2006) 1.20
NG2 proteoglycan promotes angiogenesis-dependent tumor growth in CNS by sequestering angiostatin. FASEB J (2002) 1.18
A variant in FTO shows association with melanoma risk not due to BMI. Nat Genet (2013) 1.17
Cancer initiation and progression: involvement of stem cells and the microenvironment. Biochim Biophys Acta (2007) 1.16
Permanent neonatal diabetes caused by glucokinase deficiency: inborn error of the glucose-insulin signaling pathway. Diabetes (2003) 1.15
Molecular mechanisms of temozolomide resistance in glioblastoma multiforme. Expert Rev Anticancer Ther (2012) 1.15
iTRAQ-based proteomics profiling reveals increased metabolic activity and cellular cross-talk in angiogenic compared with invasive glioblastoma phenotype. Mol Cell Proteomics (2009) 1.14
EGFR wild-type amplification and activation promote invasion and development of glioblastoma independent of angiogenesis. Acta Neuropathol (2013) 1.13
Side population in human glioblastoma is non-tumorigenic and characterizes brain endothelial cells. Brain (2013) 1.12
Atrial natriuretic peptide modulation of albumin clearance and contrast agent permeability in mouse skeletal muscle and skin: role in regulation of plasma volume. J Physiol (2009) 1.12
Mesenchymal stem cell signaling in cancer progression. Cancer Treat Rev (2012) 1.10
Replication protein A prevents accumulation of single-stranded telomeric DNA in cells that use alternative lengthening of telomeres. Nucleic Acids Res (2007) 1.10
Pancreatic lipomatosis is a structural marker in nondiabetic children with mutations in carboxyl-ester lipase. Diabetes (2007) 1.09
Anti-VEGF therapies for malignant glioma: treatment effects and escape mechanisms. Expert Opin Ther Targets (2009) 1.09
PML-nuclear bodies accumulate DNA in response to polyomavirus BK and simian virus 40 replication. Exp Cell Res (2004) 1.08
Immunohistochemical expression of stem cell, endothelial cell, and chemosensitivity markers in primary glioma spheroids cultured in serum-containing and serum-free medium. Neurosurgery (2010) 1.06
HAMLET kills tumor cells by an apoptosis-like mechanism--cellular, molecular, and therapeutic aspects. Adv Cancer Res (2003) 1.05
Targeting the NG2/CSPG4 proteoglycan retards tumour growth and angiogenesis in preclinical models of GBM and melanoma. PLoS One (2011) 1.05
SHORT syndrome with partial lipodystrophy due to impaired phosphatidylinositol 3 kinase signaling. Am J Hum Genet (2013) 1.05
Activating glucokinase (GCK) mutations as a cause of medically responsive congenital hyperinsulinism: prevalence in children and characterisation of a novel GCK mutation. Eur J Endocrinol (2008) 1.05
Combined anti-angiogenic therapy targeting PDGF and VEGF receptors lowers the interstitial fluid pressure in a murine experimental carcinoma. PLoS One (2009) 1.05
Bevacizumab treatment induces metabolic adaptation toward anaerobic metabolism in glioblastomas. Acta Neuropathol (2014) 1.04
Melanoma prone families with CDK4 germline mutation: phenotypic profile and associations with MC1R variants. J Med Genet (2013) 1.04
MicroRNAs in tumorigenesis. Curr Pharm Biotechnol (2007) 1.04
Expression of the progenitor marker NG2/CSPG4 predicts poor survival and resistance to ionising radiation in glioblastoma. Acta Neuropathol (2011) 1.03
Glioblastomas are composed of genetically divergent clones with distinct tumourigenic potential and variable stem cell-associated phenotypes. Acta Neuropathol (2013) 1.03
Interstitial fluid: the overlooked component of the tumor microenvironment? Fibrogenesis Tissue Repair (2010) 1.02
De novo HRAS and KRAS mutations in two siblings with short stature and neuro-cardio-facio-cutaneous features. J Med Genet (2007) 1.02
Human alpha-lactalbumin made lethal to tumor cells (HAMLET) kills human glioblastoma cells in brain xenografts by an apoptosis-like mechanism and prolongs survival. Cancer Res (2004) 1.01
Exome sequencing and genetic testing for MODY. PLoS One (2012) 1.00
Targeting glioblastoma with NK cells and mAb against NG2/CSPG4 prolongs animal survival. Oncotarget (2013) 0.99
Promyelocytic leukemia nuclear bodies are predetermined processing sites for damaged DNA. J Cell Sci (2006) 0.99
Mutation analysis of the EGFR-NRAS-BRAF pathway in melanomas from black Africans and other subgroups of cutaneous melanoma. Melanoma Res (2008) 0.99
Diabetes and pancreatic exocrine dysfunction due to mutations in the carboxyl ester lipase gene-maturity onset diabetes of the young (CEL-MODY): a protein misfolding disease. J Biol Chem (2011) 0.99
Molecular analysis of the EGFR-RAS-RAF pathway in pancreatic ductal adenocarcinomas: lack of mutations in the BRAF and EGFR genes. Virchows Arch (2006) 0.99
Hepatocyte nuclear factor-1 alpha gene mutations and diabetes in Norway. J Clin Endocrinol Metab (2003) 0.98
Hyperoxia retards growth and induces apoptosis and loss of glands and blood vessels in DMBA-induced rat mammary tumors. BMC Cancer (2007) 0.97
Remission of invasive, cancer stem-like glioblastoma xenografts using lentiviral vector-mediated suicide gene therapy. PLoS One (2009) 0.96